Amikacin
- PDF / 169,624 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 125 Views
1 S
Hearing loss: case report A 74-year-old man developed hearing loss while receiving treatment with amikacin for infective endocarditis (IE). The man, who had recent mitral valve replacement, presented with dyspnoea, chills and palpitations. He also reported having lower extremity oedema for a few days before presentation. At admission, blood cultures detected extended spectrum β-lactamase Escherichia coli. Based on high clinical suspicion for IE, he started receiving outpatient treatment with IV antimicrobial therapy including amikacin [dosage not stated] and ertapenem, for 6 weeks. Repeat blood cultures were negative by day 6 of antimicrobial therapy. However, five weeks after starting antimicrobial therapy, he reported having worsening of hearing loss, suggestive of aminoglycoside toxicity. Amikacin was discontinued, and the man was continued on ertapenem to complete antimicrobial therapy [outcome not stated]. Dhamrah U, et al. Successful Resolution of Early-Onset Prosthetic Valve Endocarditis Associated With Extended Spectrum beta-Lactamases Producing Escherichia coli With Medical Management. Journal of Investigative Medicine High Impact Case Reports 8: 14 Oct 2020. Available from: URL: http:// 803515460 doi.org/10.1177/2324709620965337
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
